After putting two generics together and then getting the product approved for a new indication, NitroMed priced its new drug above expectations. But will the old-style pricing strategy hold up in a managed care world?
Ellen Licking
These have been heady days for NitroMed Inc. On June 23, the Food and Drug Administration approved the company's...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
Jana Grieb, European regulatory and market access legal expert at McDermott Will & Emery, explains why the healthtech and pharma industries are warming to the new EU health commissioner as he faces calls to make the MDR more “user friendly.”
While big pharma pours billions into creating new anti-aging molecules, a Belgian startup has taken a different path: combining existing safe drugs with AI precision. The early results suggest it might be onto something revolutionary.
Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy
